SCYNEXIS (NasdaqGM:SCYX) M&A announcement March 31, 2026 08:30 AM ET Company ParticipantsDavid Angulo - CEOIvor Macleod - CFOJeremy Duffield - Chief Scientific OfficerRosana Ferrara-Pontoriero - VP of Business DevelopmentThomas Johnson - Director of Corporate CommunicationsConference Call ParticipantsKen Doliber - AnalystVamil Divan - Senior Research Analyst and Managing DirectorOperatorGreetings, and welcome to the SCYNEXIS 2026 corporate update call. At this time, all participants are on a listen-only mod ...

Advancing innovative solutions for severe rare diseases Corporate Deck March 2026 Legal Disclaimers This presentation has been prepared by SCYNEXIS, Inc. (the "Company") solely for informational purposes. This presentation contains, and our officers and representatives may from time to time make, "forward-looking statements" within the meaning of applicable securities laws and are prospective in nature, including, but not limited to, statements regarding the Company's business strategies and goals, plans an ...

PXL-770 (now SCY-770) is a clinical stage, well-characterized oral therapy designed to address the underlying drivers of ADPKD by reducing cyst growth and disease progressionA Phase 2 proof-of-concept study of SCY-770 in ADPKD patients is anticipated to begin in Q4 2026 with an early efficacy readout anticipated in the second half of 2027With this acquisition, SCYNEXIS strengthens its mission to develop innovative solutions for severe and rare diseases, unlocking further opportunities for value creation SCY ...